Real-world clinical outcomes of biologic-naive non-complicated Crohn's disease patients treated with vedolizumab: Results from the EVOLVE study

被引：0
|
作者：
Yarur, A. [1 ]
Mantzaris, G. J. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Kim, H. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Bressler, B. [12 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol, Milwaukee, WI 53226 USA
[2] Evangelismos Med Ctr, Gastroenterol, Athens, Greece
[3] Sheba Med Ctr, Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Data Analyt, Waltham, MA USA
[6] Takeda Pharmaceut USA Inc, Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA, Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] St Pauls Hosp, Gastroenterol, Vancouver, BC, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P387
引用
收藏
页码：S360 / S361
页数：2
相关论文
共 50 条
  • [41] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
    Di Giuseppe, R.
    Plachta-Danielzik, S.
    Bokemeyer, B.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I121
  • [42] Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1351 - 1365
  • [43] Characteristics of Patients With Crohn's Disease Initiating Vedolizumab Therapy in Real-World Clinical Practice
    Khalid, Javaria M.
    Reynolds, Matthew
    Alam, Naufil
    Don, O'Hara
    Smyth, Michael D. L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S773 - S774
  • [44] Effectiveness and safety of tocilizumab in monotherapy in biologic-naive and non-naive patients with rheumatoid arthritis in a real-world setting
    Marsal Barril, Sara
    Auxiliadora Martin-Martinez, Ma
    Javier Blanco-Garcia, Francisco
    Fernandez-Nebro, Antonio
    Garcia de Vicuna, Rosario
    Tornero-Molina, Jesus
    Sanchez-Alonso, Fernando
    Novella-Navarro, Marta
    Escudero-Contreras, Alejandro
    Jose Alegre-Sancho, Juan
    Urruticoechea-Arana, Ana
    Sagrario Bustabad-Reyes, Maria
    Trenor-Larraz, Pilar
    Perez-Sandoval, Trinidad
    Isabel Tevar-Sanchez, Maria
    Sanchez-Costa, Jesus T.
    Raya-Alvarez, Enrique
    REUMATOLOGIA CLINICA, 2022, 18 (10): : 567 - 573
  • [45] Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
    Patel, H.
    Khalid, J. M.
    Shah, S.
    Shah, R.
    Berger, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S385 - S386
  • [46] Effectiveness and Safety of Vedolizumab in Biologic-Naive Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
    Macaluso, F.
    Fries, W.
    Renna, S.
    Viola, A.
    Muscianisi, M.
    Cappello, M.
    Guida, L.
    Siringo, S.
    Camilleri, S.
    Garufi, S.
    Privitera, A. C.
    Belluardo, N.
    Giangreco, E.
    Bertolami, C.
    Vassallo, R.
    Rizzuto, G.
    Orlando, R.
    Ventimiglia, N.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S333 - S333
  • [47] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    di Giuseppe, R.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 543 - 543
  • [48] Endoscopic and Clinical Efficacy Demonstrated with Oral Ozanimod in Active Crohn's Disease in Biologic-Naive and Biologic Experienced Patients
    Brian, Feagan
    William, Sandborn
    Silvio, Danese
    Geert, D'Haens
    Barrett, Levesque
    Brett, Skolnick
    David, Paul
    Richard, Aranda
    Allan, Olson
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S3 - S3
  • [49] Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (08) : 3178 - 3187
  • [50] Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Yarur, A.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Mantzaris, G. J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S381 - S382
12345